SUPN / Supernus Pharmaceuticals to acquire this Pharmaceuticals company for $400 million

While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended June 2023, it could be wort more_horizontal

Supernus Pharmaceuticals (SUPN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.23. This compares to earni more_horizontal

Supernus Pharmaceuticals faces declining revenues from its long-time top seller Trokendi XR due to generic competition. Despite Trokendi's struggles, more_horizontal

Supernus Pharmaceuticals is facing generic competition for its drug Trokendi. It's also scaling up its revenue for its medicine Qelbree. more_horizontal

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to comp more_horizontal

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, more_horizontal

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.12 per share. This com more_horizontal

ROCKVILLE, Md., March 01, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing an more_horizontal